PRFX on Nasdaq
PRF Technologies Ltd.
The contents of our website are not, however, a part of this Annual Report on Form 20-F.4 From its latest annual report
Price unavailable
Last updated Oct 19, 2026.
Overview
Compare with BIOADAPTIVES, INC., SKINVISIBLE, INC. or Phio Pharmaceuticals Corp., or pick any stock.
- TickerPRFX on Nasdaq1
- IndustryPharmaceutical Preparations1
- HeadquartersL31
- Incorporated inIsrael3
- Business address65 Yigal Alon St., Tel Aviv3
- Filer categoryNon-accelerated filer3
See how the biggest companies compare on our leaderboards
The contents of our website are not, however, a part of this Annual Report on Form 20-F.4 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue3¢$70.0K
- Research and development43¢$1.1M
- Selling, general and admin54¢$1.4M
- Income tax0¢$8.0K
Out of $17.0K in revenue.2 The company lost money this year.
Financial statements
No quarterly figures reported.
Every line of the income statement as filed: the last 3 fiscal years, latest first.2
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Revenues | $17.0K | $0 | $0 |
| Cost of sales (exclusive of items shown separately below) | -$70.0K | $0 | $0 |
| Selling and marketing expenses | -$163.0K | $0 | $0 |
| Amortization of intangible assets | -$759.0K | ||
| Research and development expenses | -$1.1M | -$11.7M | -$6.0M |
| General and administrative expenses | -$3.0M | -$3.0M | -$3.5M |
| Operating loss | -$5.1M | -$14.7M | -$9.6M |
| Financial income, net | $108.0K | $93.0K | $248.0K |
| Loss before taxes | -$5.0M | -$14.6M | -$9.3M |
| Income tax expenses | -$8.0K | -$8.0K | -$8.0K |
| Comprehensive loss | -$5.0M | -$14.6M | -$9.3M |
| Comprehensive loss attributable to non-controlling interests | -$184.0K | ||
| Comprehensive loss attributable to shareholders of the Company | -$4.8M | -$14.6M | -$9.3M |
| Basic and diluted net loss per share basic | -$7.47 | -$105.52 | -$122.94 |
| Basic and diluted net loss per share diluted | -$7.47 | -$105.52 | -$122.94 |
| Weighted average number of Ordinary Share used in computing basic net loss per share | 648.0K shares | 138.3K shares | 76.0K shares |
| Ordinary Share and prefunded warrants used in computing diluted net loss per share | 648.0K shares | 138.3K shares | 76.0K shares |
No quarter-by-quarter statement was filed.
No quarterly figures reported.
Every line of the balance sheet as filed: the last 5 fiscal years (annual) or 5 quarters (quarterly), latest first.2
| Period ending | 2025-12-31 | 2025-02-28 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Cash and cash equivalents | $3.1M | $4.3M | $8.0M | ||
| Restricted cash | $25.0K | $10.0K | $10.0K | ||
| Short-term deposits | $1.0M | $0 | |||
| Prepaid expenses and other current assets | $185.0K | $157.0K | |||
| Total current assets | $4.4M | $4.4M | |||
| Intangible assets, net | $7.4M | $0 | |||
| Goodwill | $186.0K | $0 | |||
| Operating lease right of use asset | $26.0K | $62.0K | |||
| Property and equipment, net | $30.0K | $35.0K | |||
| Total non-current assets | $7.6M | $97.0K | |||
| Total assets | $12.0M | $4.5M | |||
| Trade payables | $213.0K | $296.0K | |||
| Employees and related liabilities | $339.0K | $197.0K | |||
| Operating lease liability | $21.0K | $45.0K | |||
| Accrued expenses | $1.9M | $1.9M | |||
| Total current liabilities | $2.4M | $2.4M | |||
| Provision for unrecognized tax positions | $267.0K | $259.0K | $251.0K | $243.0K | |
| Total non-current liabilities | $267.0K | $259.0K | |||
| Total liabilities | $2.7M | $2.7M | |||
| Ordinary shares, No par value; Authorized: 12,000,000 and 500,000 shares as of December 31, 2025, and 2024, respectively; Issued and outstanding: 830,613 and 341,827 shares as of December 31, 2025, and 2024, respectively | $0 | $0 | |||
| Additional paid-in capital | $69.8M | $58.3M | |||
| Accumulated deficit | -$61.3M | -$56.5M | |||
| Total equity attributable to shareholders of the Company | $8.5M | $1.8M | |||
| Non-controlling interests | $747.0K | $0 | |||
| Equity, Including Portion Attributable to Noncontrolling Interest, Total | $9.3M | $1.8M | $7.2M | $11.0M | |
| Total liabilities and equity | $12.0M | $4.5M | |||
| Common Stock, No Par Value | 0 ILS | 0 ILS | 0 ILS | ||
| Common Stock, Shares Authorized | 2.0M shares | 1.5M shares | 500.0K shares | ||
| Common Stock, Shares, Issued | 830.6K shares | 341.8K shares | |||
| Ordinary shares, shares outstanding | 830.6K shares | 341.8K shares |
| Period ending | 2025-12-31 | 2025-02-28 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Cash and cash equivalents | $3.1M | $4.3M | $8.0M | ||
| Restricted cash | $25.0K | $10.0K | $10.0K | ||
| Short-term deposits | $1.0M | $0 | |||
| Prepaid expenses and other current assets | $185.0K | $157.0K | |||
| Total current assets | $4.4M | $4.4M | |||
| Intangible assets, net | $7.4M | $0 | |||
| Goodwill | $186.0K | $0 | |||
| Operating lease right of use asset | $26.0K | $62.0K | |||
| Property and equipment, net | $30.0K | $35.0K | |||
| Total non-current assets | $7.6M | $97.0K | |||
| Total assets | $12.0M | $4.5M | |||
| Trade payables | $213.0K | $296.0K | |||
| Employees and related liabilities | $339.0K | $197.0K | |||
| Operating lease liability | $21.0K | $45.0K | |||
| Accrued expenses | $1.9M | $1.9M | |||
| Total current liabilities | $2.4M | $2.4M | |||
| Provision for unrecognized tax positions | $267.0K | $259.0K | $251.0K | $243.0K | |
| Total non-current liabilities | $267.0K | $259.0K | |||
| Total liabilities | $2.7M | $2.7M | |||
| Ordinary shares, No par value; Authorized: 12,000,000 and 500,000 shares as of December 31, 2025, and 2024, respectively; Issued and outstanding: 830,613 and 341,827 shares as of December 31, 2025, and 2024, respectively | $0 | $0 | |||
| Additional paid-in capital | $69.8M | $58.3M | |||
| Accumulated deficit | -$61.3M | -$56.5M | |||
| Total equity attributable to shareholders of the Company | $8.5M | $1.8M | |||
| Non-controlling interests | $747.0K | $0 | |||
| Equity, Including Portion Attributable to Noncontrolling Interest, Total | $9.3M | $1.8M | $7.2M | $11.0M | |
| Total liabilities and equity | $12.0M | $4.5M | |||
| Common Stock, No Par Value | 0 ILS | 0 ILS | 0 ILS | ||
| Common Stock, Shares Authorized | 2.0M shares | 1.5M shares | 500.0K shares | ||
| Common Stock, Shares, Issued | 830.6K shares | 341.8K shares | |||
| Ordinary shares, shares outstanding | 830.6K shares | 341.8K shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.2
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Consolidated Net loss | -$5.0M | -$14.6M | -$9.3M |
| Depreciation | $15.0K | $16.0K | $15.0K |
| Amortization of intangible assets | $759.0K | ||
| Exchange rate differences on cash, cash equivalents and restricted cash | $2.0K | -$6.0K | -$2.0K |
| Share-based compensation to employees and directors | $447.0K | $310.0K | $804.0K |
| Net change in operating lease asset and liability | $12.0K | -$10.0K | -$9.0K |
| Warrant issuance costs | $0 | $0 | $368.0K |
| Interest income | -$16.0K | $0 | $85.0K |
| Change in warrant liability valuation | $0 | $0 | -$1.7M |
| Loss from inducement offer letter agreement | $0 | $0 | $1.5M |
| Prepaid expenses and other current assets | -$22.0K | $1.6M | $330.0K |
| Trade payables | -$243.0K | $76.0K | $12.0K |
| Employees, related liabilities and accrued expenses | $113.0K | -$24.0K | $1.3M |
| Net cash used in operating activities | -$4.0M | -$12.6M | -$6.7M |
| Purchase of property and equipment | -$2.0K | -$13.0K | -$9.0K |
| Cash acquired through business combination | $20.0K | ||
| Proceeds from short term deposits | $0 | $7.0M | |
| Purchase of short-term deposit | -$1.0M | $0 | -$1.0M |
| Net cash provided by (used in) investing activities | -$982.0K | -$13.0K | $6.0M |
| Proceeds from issuance of shares, warrants and prefunded warrants | $8.0K | $4.0M | $1.7M |
| Proceeds from exercise of warrants | $0 | $3.2M | $2.5M |
| Proceeds from exercise and issuance of warrants | $0 | $1.6M | $1.3M |
| Proceeds from issuance of Ordinary shares At-the market offering | $4.0M | $1.4M | $0 |
| Issuance costs | -$190.0K | -$1.2M | -$932.0K |
| Net cash provided by financing activities | $3.8M | $8.9M | $4.6M |
| Effect of Exchange rate changes on cash, cash equivalents and restricted cash | -$2.0K | $6.0K | $2.0K |
| Change in cash, cash equivalents and restricted cash | -$1.1M | -$3.8M | $3.9M |
| Acquisition of right-of-use assets by means of lease liabilities | $49.0K | $0 | $113.0K |
| Acquisition of technology in exchange for equity instruments | $7.3M | $0 | $0 |
No quarter-by-quarter statement was filed.
Leadership
Who has led PRF Technologies Ltd., and when. Pick a name to see everywhere that person has worked.
Chief executive
Chair
Chief financial officer
Chief operating officer
- Chief executive officerEfraim Cohen-Arazi Mar 18, 2026 to now10
- ChairEhud Geller Mar 18, 2026 to now11
- Chief financial officerEyal Broder Mar 18, 2026 to now12
- Chief operating officerSigal Aviel Mar 18, 2026 to now13
Board members and other officers (4)
- Board memberAsaf Shavit Mar 18, 2026 to now14
- Board memberAugustine Lawlor Mar 18, 2026 to now15
- Board memberEfraim Cohen-Arazi Mar 18, 2026 to now10
- Board memberEllen S. Baron Mar 18, 2026 to now16
Former names
- PAINREFORM LTD.Feb 3, 2020 to Jan 20, 20263
Timeline
- Mar 18, 2026New chief executive Efraim Cohen-Arazi becomes CEO10
Filings
195 filings to the SEC since October 2021: 5 annual reports, 7 insider forms, 16 large holders, 167 other. The latest 20:
- Sep 28, 20266-K EDGAR
- Sep 24, 2026SCHEDULE 13D EDGAR
- Sep 16, 20266-K EDGAR
- Sep 9, 20266-K EDGAR
- Sep 3, 2026EFFECT EDGAR
- Sep 3, 2026POS AM EDGAR
- Sep 3, 20266-K EDGAR
- Jul 27, 20266-K EDGAR
- Jul 21, 20266-K EDGAR
- Jul 15, 20266-K EDGAR
- Jul 8, 20266-K EDGAR
- Jun 29, 2026EFFECT EDGAR
- Jun 29, 2026424B3 EDGAR
- Jun 29, 2026CORRESP EDGAR
- Jun 26, 2026UPLOAD EDGAR
- Jun 25, 20266-K EDGAR
- Jun 22, 2026F-1 EDGAR
- Jun 22, 2026SCHEDULE 13G/A EDGAR
- Jun 18, 20266-K EDGAR
- Jun 16, 2026SCHEDULE 13G/A EDGAR
The 195 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- S.H.N. Financial Investments Ltd.SCHEDULE 13D, 1 filing Sep 24, 202617
- YA II PN, Ltd.SCHEDULE 13G/A, 2 filings May 12, 2026 to Jun 22, 202618
- Blade Ranger Ltd.SCHEDULE 13G/A, 2 filings Apr 24, 2025 to Jun 16, 202619
- ARMISTICE CAPITAL, LLCSC 13G/A, 2 filings Feb 14, 2024 to Nov 14, 202420
- INTRACOASTAL CAPITAL, LLCSC 13G/A, 2 filings Apr 24, 2024 to Nov 13, 202421
- L.I.A. Pure Capital LtdSC 13D/A, 2 filings Aug 26, 2024 to Aug 29, 202422
- Ehud GellerSC 13G/A, 3 filings Feb 11, 2022 to Feb 15, 202423
- XT Holdings Ltd.SC 13G/A, 2 filings Jan 25, 2022 to Jan 23, 202424
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11SEC EDGAREhud Geller, Chair
- 12SEC EDGAREyal Broder, Chief financial officer
- 13SEC EDGARSigal Aviel, Chief operating officer
- 14SEC EDGARAsaf Shavit, Board member
- 15SEC EDGARAugustine Lawlor, Board member
- 16SEC EDGAREllen S. Baron, Board member
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24